In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins
Author(s) -
Irene Maffucci,
Alessandro Contini
Publication year - 2020
Publication title -
journal of proteome research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.644
H-Index - 161
eISSN - 1535-3907
pISSN - 1535-3893
DOI - 10.1021/acs.jproteome.0c00383
Subject(s) - in silico , repurposing , drug repositioning , virtual screening , covid-19 , drug discovery , computational biology , drug , spike (software development) , spike protein , docking (animal) , virology , drug development , biology , pharmacology , bioinformatics , computer science , medicine , biochemistry , infectious disease (medical specialty) , gene , ecology , disease , software engineering , nursing , pathology , outbreak
The pandemic caused by SARS-CoV-2 is currently representing a major health and economic threat to humanity. So far, no specific treatment to this viral infection has been developed and the emergency still requires an efficient intervention. In this work, we used virtual screening to facilitate drug repurposing against SARS-CoV-2, targeting viral main proteinase and spike protein with 3000 existing drugs. We used a protocol based on a docking step followed by a short molecular dynamic simulation and rescoring by the Nwat-MMGBSA approach. Our results provide suggestions for prioritizing in vitro and/or in vivo tests of already available compounds.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom